Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Tolerability of Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children: a Comparative Study.

NCT02327936 is registered in ClinicalTrials.gov with Stéphane Bolduc as lead sponsor.

NCT NCT02327936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02327936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Tolerability of Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children: a Comparative Study.
Lead sponsor
Stéphane Bolduc
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2014
Completion date
August 31, 2018
Enrollment
62 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder